Seth Klarman Picks Enzon, Idenix a Mixed Bag This Tuesday

Seth Klarman Picks Enzon, Idenix a Mixed Bag This Tuesday

Today’s top midday gainers are Enzon Pharmaceuticals Inc (NASDAQ:ENZN), Idenix Pharmaceuticals Inc (NASDAQ:IDIX) and Navios Maritime Holdings Inc. (NYSE:NM).  The losers are Kindred Biosciences Inc (NASDAQ:KIN), Dex Media Inc (NASDAQ:DXM) and B&W Company (NYSE:BWC).

Play Quizzes 4

Enzon, Idenix  Surge

Up +7.92% is Enzon Pharmaceuticals Inc (NASDAQ:ENZN), a firm in the portfolios of both Seth Klarman and Carl Icahn.

How Value Investors Can Win With Tech And “Fallen” Growth Stocks

Valuation Present ValueMany value investors have given up on their strategy over the last 15 years amid concerns that value investing no longer worked. However, some made small adjustments to their strategy but remained value investors to the core. Now all of the value investors who held fast to their investment philosophy are being rewarded as value Read More

A second Klarman pharmaceutical pick is also having a strong start to the day – Idenix Pharmaceuticals Inc (NASDAQ:IDIX), the price of which surged +4.38. Like Enzon, Idenix released results last week, and its price has surged +8.35% since.

Rounding out our list of midday gainers this Tuesday is George Soros bet Navios Maritime Holdings Inc. (NYSE:NM), up +3.98%. Despite today’s gain, NM is down -22.22% for the year.

Kindred Biosciences Slides

Not all of Klarman’s pharmaceutical picks are hitting it out of the park today. Biopharmaceutical company Kindred Biosciences Inc (NASDAQ:KIN) lost -9.08% after missing expectations on its quarterly results. Farallon Capital Management joins Klarman in betting on this one.

The share price of Dex Media Inc (NASDAQ:DXM) fell -8.14% – a notable reverse given that the John Paulson asset has jumped +31.63% since announcing plans to announce results last week.

Down -6.09% is David Einhorn pick B&W Company. News recently came out that it will be acquiring MEGTEC, an industrial processes solutions provider, for $155 million.

Updated on

No posts to display